Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B.

Yao-Chun HsuTomi JunYen-Tsung HuangMing-Lun YehChia-Long LeeShintaro OgawaShu-Hsien ChoJaw-Town LinMing-Lung YuMindie H NguyenYasuhito Tanaka

Published in: Alimentary pharmacology & therapeutics (2018)

Serum M2BPGi level significantly decreases after NA treatment in CHB patients. Baseline level can be factored into the risk prediction of HCC in NA-treated patients with cirrhosis.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
hepatitis b virus
sars cov
prognostic factors
patient reported outcomes